Australia markets close in 52 minutes

Anavex Life Sciences Corp. (AVXL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
10.93-0.82 (-6.98%)
At close: 04:00PM EST
11.08 +0.15 (+1.37%)
After hours: 07:46PM EST
Full screen
Trade prices are not sourced from all markets
Previous close11.75
Open11.51
Bid11.05 x 800
Ask11.02 x 900
Day's range10.92 - 11.89
52-week range7.13 - 15.24
Volume1,419,648
Avg. volume2,482,678
Market cap852.891M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.58
Earnings date08 May 2023 - 12 May 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est48.80
  • Motley Fool

    Why Anavex Life Sciences Stock Bolted Higher in January

    The biotech's shares have been steadily leaking higher following positive late-stage Alzheimer's disease trial results.

  • GlobeNewswire

    Anavex Life Sciences Reports Fiscal 2023 First Quarter Financial Results

    Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today reported financial results for its fiscal quarter en

  • GlobeNewswire

    Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial

    NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced the total enrollment of 92 patients with Rett syndrome for the ANAVEX®2-73 (blarcamesine) EXCELLENCE